Cibinqo Side Effects: What to Expect and When to Call Your Doctor

Cibinqo (abrocitinib) is an effective oral treatment for moderate-to-severe atopic dermatitis, but like all medications — especially those that affect the immune system — it comes with a range of potential side effects. Knowing what to expect, what to watch for, and when to seek medical attention can make a significant difference in your safety and treatment success.

Important: Cibinqo carries a boxed warning — the FDA's most serious warning — for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Read this guide carefully and always discuss your personal risk factors with your prescriber.

Common Side Effects of Cibinqo (What Most Patients Experience)

In Phase 3 clinical trials, the most frequently reported side effects (occurring in ≥1% of Cibinqo-treated patients at a higher rate than placebo) included:

Nasopharyngitis (runny nose, stuffy nose, sore throat) — the most common side effect

Nausea — often mild and occurs early in treatment; taking Cibinqo with food may help

Headache — reported in clinical trials; generally mild

Herpes simplex (cold sores, oral herpes, genital herpes flares) — more frequent with Cibinqo than placebo due to immune modulation

Increased blood creatine phosphokinase (CPK) — a lab finding; discuss with your doctor what this means for you

Dizziness, fatigue, acne, vomiting — all reported in a minority of patients

Urinary tract infection (UTI) — keep an eye out for burning urination or increased frequency

Hypertension — blood pressure may rise; monitor regularly, especially if you have preexisting cardiovascular risk factors

Thrombocytopenia (low platelet count) — Cibinqo causes a transient, dose-dependent decrease in platelet count with a nadir at approximately 24 days; platelets typically recover without stopping treatment

Serious Side Effects: The Boxed Warning Explained

Cibinqo's boxed warning covers five categories of serious risks shared across the JAK inhibitor drug class. These risks were identified in studies of JAK inhibitors in patients with rheumatoid arthritis and are applied to all approved JAK inhibitors, including abrocitinib.

Serious infections: Including herpes zoster (shingles), pneumonia, tuberculosis, and invasive fungal infections. Get vaccinated for shingles (zoster) before starting Cibinqo if not already vaccinated.

Mortality: A higher rate of all-cause mortality was seen with another JAK inhibitor in a postmarketing RA safety study. This has been applied as a class warning.

Malignancy: Lymphoma and other cancers have been reported with JAK inhibitor use. Avoid Cibinqo if you have current or recent malignancy.

Major adverse cardiovascular events (MACE): Including heart attack and stroke. Risk is higher in patients 65+, smokers, or those with existing cardiovascular risk factors.

Thrombosis: Deep vein thrombosis (DVT) and pulmonary embolism have been reported. If you have risk factors for blood clots, discuss these with your doctor before starting Cibinqo.

Laboratory Abnormalities to Monitor

Your doctor will order labs before and during Cibinqo treatment to catch early warning signs:

CBC: low platelets (stop if <50,000/mm3), low lymphocytes, low neutrophils

Hemoglobin: stop if hemoglobin falls below 8 g/dL

Lipid panel: Cibinqo can raise LDL and total cholesterol levels

When Should You Call Your Doctor Immediately?

Stop taking Cibinqo and seek medical attention right away if you experience:

Signs of serious infection: fever, chills, body aches, cough, shortness of breath, skin infection that doesn't improve

Signs of blood clot: sudden leg pain or swelling, chest pain, sudden shortness of breath

Sudden vision changes — retinal detachment has been reported in Cibinqo clinical trials

Unusual or easy bruising or bleeding (possible sign of very low platelets)

Chest pain, jaw pain, left arm pain (possible signs of heart attack)

37,512+ patients found their medications in stock

37K+

Find Cibinqo In Stock Today →

Managing Nausea and Other Common Side Effects

Nausea is one of the most commonly reported early side effects of Cibinqo. It typically improves over time. Practical tips:

Take Cibinqo with food to reduce stomach upset

Stay hydrated and avoid taking on an empty stomach

If nausea persists beyond the first few weeks, contact your prescriber — a dose adjustment to 100 mg may help

Should You Be Worried About Side Effects?

The boxed warning sounds alarming, but for most patients without significant underlying cardiovascular disease, cancer history, or infection risk, Cibinqo's benefit-risk profile is favorable — especially for moderate-to-severe atopic dermatitis that hasn't responded to other treatments. The serious risks in the boxed warning are more relevant to older patients and those with underlying health conditions. Talk openly with your dermatologist about your personal risk profile. Also be sure to read about Cibinqo drug interactions to make sure your other medications are safe to take alongside it.

Once you're ready to fill your Cibinqo prescription, medfinder can help you find a pharmacy near you that has it in stock.